



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(51) International Patent Classification (IPC):  
**A61K 31/138** <sup>(2006.01)</sup> **A61K 31/439** <sup>(2006.01)</sup>  
**A61K 31/58** <sup>(2006.01)</sup> **A61P 11/06** <sup>(2006.01)</sup>  
**A61P 11/00** <sup>(2006.01)</sup> **A61K 9/00** <sup>(2006.01)</sup>

(48) Corrigendum issued on:  
**11.10.2023 Bulletin 2023/41**

(52) Cooperative Patent Classification (CPC):  
(C-Sets available)  
**A61K 31/58; A61K 9/0075; A61K 31/138;**  
**A61K 31/439; A61P 11/00; A61P 11/06;**  
**A61P 43/00**

(Cont.)

(45) Date of publication and mention  
of the grant of the patent:  
**06.09.2023 Bulletin 2023/36**

(21) Application number: **19214674.4**

(22) Date of filing: **27.05.2015**

(54) **FLUTICASONE FUROATE IN THE TREATMENT OF COPD**

FLUTICASONFUROAT BEI DER BEHANDLUNG VON COPD

FUROATE DE FLUTICASONE UTILISÉ DANS LE TRAITEMENT DE LA BPCO

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB**  
**GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO**  
**PL PT RO RS SE SI SK SM TR**  
Designated Extension States:  
**BA ME**

(72) Inventors:  
• **BARNES, Neil Christopher**  
**Uxbridge, Middlesex UB7 8JJ (GB)**  
• **PASCOE, Steven John**  
**Research Triangle Park, North Carolina 27709**  
**(US)**

(30) Priority: **28.05.2014 US 201462003764 P**  
**29.05.2014 US 201462004304 P**  
**27.08.2014 US 201462042506 P**

(74) Representative: **Fowler, Gavin James**  
**GlaxoSmithKline**  
**Global Patents (CN925.1)**  
**980 Great West Road**  
**Brentford, Middlesex TW8 9GS (GB)**

(43) Date of publication of application:  
**13.05.2020 Bulletin 2020/20**

(56) References cited:  
**WO-A1-2011/067212**

(60) Divisional application:  
**23191900.2 / 4 252 742**

(62) Document number(s) of the earlier application(s) in  
accordance with Art. 76 EPC:  
**15726106.6 / 3 148 521**

• **MONA BAFADHEL ET AL: "Blood Eosinophils to**  
**Direct Corticosteroid Treatment of Exacerbations**  
**of Chronic Obstructive Pulmonary Disease",**  
**AMERICAN JOURNAL OF RESPIRATORY AND**  
**CRITICAL CARE MEDICINE, vol. 186, no. 1, 1 July**  
**2012 (2012-07-01), pages 48-55, XP055204840,**  
**ISSN: 1073-449X, DOI:**  
**10.1164/rccm.201108-1553OC**

(73) Proprietor: **GlaxoSmithKline Intellectual Property**  
**Development**  
**Limited**  
**Stevenage SG1 2NY (GB)**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- PASCOE STEVEN ET AL: "Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.", THE LANCET. RESPIRATORY MEDICINE JUN 2015, vol. 3, no. 6, 13 April 2015 (2015-04-13), pages 435-442, XP008177095, ISSN: 2213-2619
- NEIL C. BARNES ET AL: "Blood eosinophils as a marker of response to inhaled corticosteroids in COPD", EUROPEAN RESPIRATORY JOURNAL, vol. 47, no. 5, 25 February 2016 (2016-02-25), pages 1374-1382, XP055522832, GB ISSN: 0903-1936, DOI: 10.1183/13993003.01370-2015

(52) Cooperative Patent Classification (CPC): (Cont.)

C-Sets

**A61K 31/138, A61K 2300/00;**

**A61K 31/439, A61K 2300/00;**

**A61K 31/58, A61K 2300/00**